EC Number | Application | Comment | Organism |
---|---|---|---|
2.3.1.21 | pharmacology | CPT I, model enzyme for studies of fatty acid-induced apoptosis in cancer therapy | Rattus norvegicus |
EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
2.3.1.21 | gamma-linolenic acid | inhibits CPT I in vivo and reduces malonyl-CoA sensitivity, decreases affinity for 16:0 acyl-CoA substrate | Rattus norvegicus | |
2.3.1.21 | malonyl-CoA | CPT I, sensitivity is reduced in vivo during gamma-linolenic acid treatment; membrane or micelle composition and properties influence the sensitivity of CPT I to inhibition | Rattus norvegicus |
EC Number | KM Value [mM] | KM Value Maximum [mM] | Substrate | Comment | Organism | Structure |
---|---|---|---|---|---|---|
2.3.1.21 | 0.011 | - |
palmitoyl-CoA | CPT I | Rattus norvegicus | |
2.3.1.21 | 0.017 | - |
palmitoyl-CoA | CPT I after gamma-linoleic acid treatment | Rattus norvegicus | |
2.3.1.21 | 0.092 | - |
L-carnitine | CPT I | Rattus norvegicus | |
2.3.1.21 | 0.098 | - |
L-carnitine | CPT I after gamma-linoleic acid treatment | Rattus norvegicus |
EC Number | Localization | Comment | Organism | GeneOntology No. | Textmining |
---|---|---|---|---|---|
2.3.1.21 | mitochondrial outer membrane | CPT I is located in the outer membrane | Rattus norvegicus | 5741 | - |
2.3.1.21 | mitochondrion | - |
Rattus norvegicus | 5739 | - |
2.3.1.21 | additional information | composition of the outer mitochondrial membrane is important for functionality and activity of CPT I | Rattus norvegicus | - |
- |
EC Number | Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
2.3.1.21 | acyl-CoA + L-carnitine | Rattus norvegicus | enzyme is involved in apoptosis induction | CoA + L-acylcarnitine | - |
? | |
2.3.1.21 | additional information | Rattus norvegicus | gamma-linolenic acid diet leads to several physiological effects during cancer therapy, e.g. reduction of mitochondrial metabolic activity, modification of mitochondrial outer membrane composition, increase in lipid peroxidation, cytoplasmic accumulation of acyl-CoA, reduction of CPT I activity, and malonyl-CoA sensitivity | ? | - |
? |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
2.3.1.21 | Rattus norvegicus | - |
enzyme form CPT I | - |
2.3.1.21 | Rattus norvegicus | - |
Walker 256 tumour rat | - |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
2.3.1.21 | Walker carcinoma 256 cell | CPT I | Rattus norvegicus | - |
EC Number | Specific Activity Minimum [µmol/min/mg] | Specific Activity Maximum [µmol/min/mg] | Comment | Organism |
---|---|---|---|---|
2.3.1.21 | 0.0014 | - |
CPT I after gamma-linoleic acid treatment | Rattus norvegicus |
2.3.1.21 | 0.0036 | - |
CPT I | Rattus norvegicus |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
2.3.1.21 | acyl-CoA + L-carnitine | activity with different substrates of wild-type CPT I with and without gamma-linoleic acid treatment | Rattus norvegicus | CoA + L-acylcarnitine | - |
? | |
2.3.1.21 | acyl-CoA + L-carnitine | enzyme is involved in apoptosis induction | Rattus norvegicus | CoA + L-acylcarnitine | - |
? | |
2.3.1.21 | additional information | gamma-linolenic acid diet leads to several physiological effects during cancer therapy, e.g. reduction of mitochondrial metabolic activity, modification of mitochondrial outer membrane composition, increase in lipid peroxidation, cytoplasmic accumulation of acyl-CoA, reduction of CPT I activity, and malonyl-CoA sensitivity | Rattus norvegicus | ? | - |
? | |
2.3.1.21 | palmitoyl-CoA + L-carnitine | - |
Rattus norvegicus | CoA + L-palmitoylcarnitine | - |
? |
EC Number | Temperature Optimum [°C] | Temperature Optimum Maximum [°C] | Comment | Organism |
---|---|---|---|---|
2.3.1.21 | 37 | - |
assay at | Rattus norvegicus |